{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T09:29:50Z","timestamp":1766050190091,"version":"build-2065373602"},"reference-count":36,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,28]],"date-time":"2024-01-28T00:00:00Z","timestamp":1706400000000},"content-version":"am","delay-in-days":361,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surgjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgery"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.surg.2022.10.009","type":"journal-article","created":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T07:56:27Z","timestamp":1669190187000},"page":"305-311","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Risk factors for breast cancer mortality after ductal carcinoma in situ diagnosis differ from those for invasive recurrence"],"prefix":"10.1016","volume":"173","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1439-8569","authenticated-orcid":false,"given":"Thomas J.","family":"O\u2019Keefe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harrison","family":"Chau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Harismendy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2919-2491","authenticated-orcid":false,"given":"Anne M.","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.surg.2022.10.009_bib1","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pky063","article-title":"Epidemiology, biology, treatment, and prevention of ductal carcinoma in situ (DCIS)","volume":"2","author":"Punglia","year":"2018","journal-title":"JNCI Cancer Spectr"},{"key":"10.1016\/j.surg.2022.10.009_bib2","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1093\/jncimonographs\/lgq039","article-title":"Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast","volume":"2010","author":"Correa","year":"2010","journal-title":"J\u00a0Natl Cancer Inst Monogr"},{"key":"10.1016\/j.surg.2022.10.009_bib3","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1146\/annurev-med-050715-104920","article-title":"Controversies in the treatment of ductal carcinoma in situ. Ann","volume":"68","author":"Barrio","year":"2017","journal-title":"Rev Med"},{"key":"10.1016\/j.surg.2022.10.009_bib4","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1001\/jamaoncol.2015.2510","article-title":"Breast cancer mortality after a diagnosis of ductal carcinoma in situ","volume":"1","author":"Narod","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.surg.2022.10.009_bib5","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1093\/jnci\/94.20.1546","article-title":"Detection of ductal carcinoma in situ in women undergoing screening mammography","volume":"94","author":"Ernster","year":"2002","journal-title":"JNCI J Natl Cancer Inst"},{"key":"10.1016\/j.surg.2022.10.009_bib6","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/jncimono\/1997.22.151","article-title":"Increases in ductal carcinoma in situ (DCIS) of the breast in relation to mammography: a dilemma","volume":"1997","author":"Ernster","year":"1997","journal-title":"JNCI Monogr"},{"key":"10.1016\/j.surg.2022.10.009_bib7","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/s41416-019-0478-6","article-title":"Ductal carcinoma in situ: to treat or not to treat, that is the question","volume":"121","author":"van Seijen","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.surg.2022.10.009_bib8","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-026797","article-title":"The COMET (Comparison of Operative versus Monitoring and Endocrine Therapy) trial: a phase III randomised controlled clinical trial for low-risk ductal carcinoma in situ (DCIS)","volume":"9","author":"Hwang","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.surg.2022.10.009_bib9","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1016\/j.ejca.2015.07.017","article-title":"Addressing overtreatment of screen detected DCIS; the LORIS trial","volume":"51","author":"Francis","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.surg.2022.10.009_bib10","first-page":"1497","article-title":"Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ: the LORD study","volume":"51","author":"Elshof","year":"2015","journal-title":"Eur J Cancer (Oxf Engl). 1990"},{"key":"10.1016\/j.surg.2022.10.009_bib11","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS603","article-title":"The international collaboration of active surveillance trials for low-risk DCIS (LORIS, LORD, COMET, LORETTA)","volume":"37","author":"Kanbayashi","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.surg.2022.10.009_bib12","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s10549-020-05733-z","article-title":"Surveillance, Epidemiology, and End Results program underestimates breast cancer-specific mortality after ductal carcinoma in situ diagnosis","volume":"182","author":"O\u2019Keefe","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.surg.2022.10.009_bib13","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11912-019-0777-3","article-title":"Management of ductal carcinoma in situ (DCIS) of the breast: present approaches and future directions","volume":"21","author":"Solin","year":"2019","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.surg.2022.10.009_bib14","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1200\/JCO.2011.36.2574","article-title":"Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry","volume":"30","author":"Iwamoto","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.surg.2022.10.009_bib15","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1200\/JCO.2009.25.6529","article-title":"American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer","volume":"28","author":"Hammond","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.surg.2022.10.009_bib16","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1214\/aos\/1176350951","article-title":"A\u00a0class of $K$-sample tests for comparing the cumulative incidence of a competing risk","volume":"16","author":"Gray","year":"1988","journal-title":"Ann Stat"},{"key":"10.1016\/j.surg.2022.10.009_bib17","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A\u00a0proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J\u00a0Am Stat Assoc"},{"key":"10.1016\/j.surg.2022.10.009_bib18","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s10147-021-02036-1","article-title":"Large and diffuse ductal carcinoma in situ: potentially lethal subtypes of \u201cpreinvasive\u201d disease","volume":"27","author":"O\u2019Keefe","year":"2022","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.surg.2022.10.009_bib19","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1002\/cncr.23052","article-title":"Clinical relevance of the distribution of the lesions in 500 consecutive breast cancer cases documented in large-format histologic sections","volume":"110","author":"Tot","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.surg.2022.10.009_bib20","doi-asserted-by":"crossref","first-page":"307","DOI":"10.21037\/gs-21-599","article-title":"Histopathological growth distribution of ductal carcinoma in situ: tumor size is not \u201cone size fits all","volume":"11","author":"O\u2019Keefe","year":"2022","journal-title":"Gland Surg"},{"key":"10.1016\/j.surg.2022.10.009_bib28","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/01.pap.0000184177.65919.5e","article-title":"Prognostic and predictive molecular markers in DCIS: a review","volume":"12","author":"Nofech-Mozes","year":"2005","journal-title":"Adv Anat Pathol"},{"key":"10.1016\/j.surg.2022.10.009_bib29","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1158\/1940-6207.CAPR-20-0024","article-title":"HER2-overexpressing ductal carcinoma in situ associated with increased risk of ipsilateral invasive recurrence, receptor discordance with recurrence","volume":"13","author":"O\u2019Keefe","year":"2020","journal-title":"Cancer Prev Res (Phila Pa)"},{"key":"10.1016\/j.surg.2022.10.009_bib30","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1186\/s12885-015-1479-3","article-title":"The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS): a population-based cohort study","volume":"15","author":"Borgquist","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.surg.2022.10.009_bib31","doi-asserted-by":"crossref","DOI":"10.1097\/PAI.0000000000000223","article-title":"Her2 and Ki67 biomarkers predict recurrence of ductal carcinoma in situ","volume":"24","author":"Davis","year":"2016","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.surg.2022.10.009_bib32","first-page":"7","article-title":"Biological markers predictive of invasive recurrence in DCIS","volume":"2","author":"Nofech-Mozes","year":"2008","journal-title":"Clin Med Oncol"},{"key":"10.1016\/j.surg.2022.10.009_bib24","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0002-9610(03)00265-4","article-title":"The University of Southern California\/Van Nuys prognostic index for ductal carcinoma in situ of the breast","volume":"186","author":"Silverstein","year":"2003","journal-title":"Am J Surg"},{"key":"10.1016\/j.surg.2022.10.009_bib25","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1002\/(SICI)1097-0142(19960601)77:11<2267::AID-CNCR13>3.0.CO;2-V","article-title":"A\u00a0prognostic index for ductal carcinoma in situ of the breast","volume":"77","author":"Silverstein","year":"1996","journal-title":"Cancer"},{"key":"10.1016\/j.surg.2022.10.009_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10549-011-1387-4","article-title":"Tumor characteristics as predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis","volume":"127","author":"Wang","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.surg.2022.10.009_bib38","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/sj.bjc.6605718","article-title":"A\u00a0new pathological system for grading DCIS with improved prediction of local recurrence: results from the UKCCCR\/ANZ DCIS trial","volume":"103","author":"Pinder","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.surg.2022.10.009_bib23","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1093\/jnci\/djg097","article-title":"Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy","volume":"95","author":"Kerlikowske","year":"2003","journal-title":"JNCI J Natl Cancer Inst"},{"key":"10.1016\/j.surg.2022.10.009_bib39","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s10549-014-3151-z","article-title":"Racial disparities in risk of second breast tumors after ductal carcinoma in situ","volume":"148","author":"Liu","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.surg.2022.10.009_bib40","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1002\/cncr.32200","article-title":"Race and risk of subsequent aggressive breast cancer following ductal carcinoma in situ","volume":"125","author":"Liu","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.surg.2022.10.009_bib41","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s10549-007-9807-1","article-title":"Risk of second primary breast cancers among women with ductal carcinoma in situ of the breast","volume":"111","author":"Innos","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.surg.2022.10.009_bib42","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s10549-016-4030-6","article-title":"Comparing treatment and outcomes of ductal carcinoma in situ among women in Missouri by race","volume":"160","author":"Madubata","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.surg.2022.10.009_bib21","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.17124","article-title":"Association of a diagnosis of ductal carcinoma in situ with death from breast cancer","volume":"3","author":"Giannakeas","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.surg.2022.10.009_bib22","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.1100","article-title":"Association of radiotherapy with survival in women treated for ductal carcinoma in situ with lumpectomy or mastectomy","volume":"1","author":"Giannakeas","year":"2018","journal-title":"JAMA Netw Open"}],"container-title":["Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039606022008765?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039606022008765?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T11:03:10Z","timestamp":1758538990000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039606022008765"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S0039606022008765"],"URL":"https:\/\/doi.org\/10.1016\/j.surg.2022.10.009","relation":{},"ISSN":["0039-6060"],"issn-type":[{"type":"print","value":"0039-6060"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk factors for breast cancer mortality after ductal carcinoma in situ diagnosis differ from those for invasive recurrence","name":"articletitle","label":"Article Title"},{"value":"Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.surg.2022.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}